Navigation Links
AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Date:9/1/2009

QUEBEC CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, M.D., will present a corporate overview at the upcoming Rodman Renshaw Annual Global Investment Conference on Wednesday, September 9, 2009 at 12:30 p.m. (eastern time) in the Spellman Salon (5th floor) of the New York Palace Hotel in New York City.

A live webcast of the presentation will be available on AEterna Zentaris' website at www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
4. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
5. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
6. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
7. AEterna Zentaris Receives US$10 Million from Institutional Investors
8. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
9. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
11. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... NeuMedics Inc. ... podium presentation at Life Science Innovation Northwest on June 2, 2016. The session begins ... NeuMedics compound and propriety microemulsion can be successfully used as a topical agent and ...
(Date:5/27/2016)... , May 27, 2016 At ... investors playing in this space know that volatility is what ... featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... Lpath Inc. (NASDAQ: LPTN ), and Heat Biologics ... gain access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... variety of fracture-specific plating options designed to address fractures of the distal tibia ... solutions. , The Acumed Ankle Plating System 3 is composed of seven plate ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):